Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C47H58N12O6 |
| Molecular Weight | 887.0402 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](NC(=O)[C@@H](CC1=C(C)NC2=CC=CC=C12)NC(=O)[C@@H](N)CC3=CN=CN3)C(=O)N[C@@H](CC4=CNC5=C4C=CC=C5)C(=O)N[C@H](CC6=CC=CC=C6)C(=O)N[C@@H](CCCCN)C(N)=O
InChI
InChIKey=RVWNMGKSNGWLOL-GIIHNPQRSA-N
InChI=1S/C47H58N12O6/c1-27-34(33-15-7-9-17-37(33)54-27)23-41(58-44(62)35(49)22-31-25-51-26-53-31)45(63)55-28(2)43(61)57-40(21-30-24-52-36-16-8-6-14-32(30)36)47(65)59-39(20-29-12-4-3-5-13-29)46(64)56-38(42(50)60)18-10-11-19-48/h3-9,12-17,24-26,28,35,38-41,52,54H,10-11,18-23,48-49H2,1-2H3,(H2,50,60)(H,51,53)(H,55,63)(H,56,64)(H,57,61)(H,58,62)(H,59,65)/t28-,35-,38-,39+,40-,41+/m0/s1
Examorelin (Hexarelin) is a hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) that stimulates the release of growth hormone lease through binding to the growth hormone secretagogue receptor (GHSR). Hexarelin might have direct cardiovascular actions beyond growth hormone release and neuroendocrine effects. Europeptides and Mediolanum Farmaceutici were developing examorelin for the treatment of somatotropin deficiency.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat. | 2010-04 |
|
| The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency. | 1995-09 |
|
| Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. | 1994-03 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8126144
i.v. (1 and 2 ug/kg), sc (1.5 and 3 ug/kg), intranasal (20 ug/kg), and oral (po; 20 and 40 mg)
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-Examorelin
Created by
admin on Wed Apr 02 09:24:21 GMT 2025 , Edited by admin on Wed Apr 02 09:24:21 GMT 2025
|
||
|
NCI_THESAURUS |
C76358
Created by
admin on Wed Apr 02 09:24:21 GMT 2025 , Edited by admin on Wed Apr 02 09:24:21 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C76092
Created by
admin on Wed Apr 02 09:24:21 GMT 2025 , Edited by admin on Wed Apr 02 09:24:21 GMT 2025
|
PRIMARY | |||
|
09QF37C617
Created by
admin on Wed Apr 02 09:24:21 GMT 2025 , Edited by admin on Wed Apr 02 09:24:21 GMT 2025
|
PRIMARY | |||
|
7078
Created by
admin on Wed Apr 02 09:24:21 GMT 2025 , Edited by admin on Wed Apr 02 09:24:21 GMT 2025
|
PRIMARY | |||
|
140703-51-1
Created by
admin on Wed Apr 02 09:24:21 GMT 2025 , Edited by admin on Wed Apr 02 09:24:21 GMT 2025
|
PRIMARY | |||
|
CHEMBL108335
Created by
admin on Wed Apr 02 09:24:21 GMT 2025 , Edited by admin on Wed Apr 02 09:24:21 GMT 2025
|
PRIMARY | |||
|
100000081548
Created by
admin on Wed Apr 02 09:24:21 GMT 2025 , Edited by admin on Wed Apr 02 09:24:21 GMT 2025
|
PRIMARY | |||
|
DTXSID401032408
Created by
admin on Wed Apr 02 09:24:21 GMT 2025 , Edited by admin on Wed Apr 02 09:24:21 GMT 2025
|
PRIMARY | |||
|
EXAMORELIN
Created by
admin on Wed Apr 02 09:24:21 GMT 2025 , Edited by admin on Wed Apr 02 09:24:21 GMT 2025
|
PRIMARY | |||
|
SUB07490MIG
Created by
admin on Wed Apr 02 09:24:21 GMT 2025 , Edited by admin on Wed Apr 02 09:24:21 GMT 2025
|
PRIMARY | |||
|
C086184
Created by
admin on Wed Apr 02 09:24:21 GMT 2025 , Edited by admin on Wed Apr 02 09:24:21 GMT 2025
|
PRIMARY | |||
|
6918297
Created by
admin on Wed Apr 02 09:24:21 GMT 2025 , Edited by admin on Wed Apr 02 09:24:21 GMT 2025
|
PRIMARY |
ACTIVE MOIETY